Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis. — CFSMEATLAS
Revisiting IgG Antibody Reactivity to Epstein-Barr Virus in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Its Potential Application to Disease Diagnosis.
Sepúlveda, Nuno, Malato, João, Sotzny, Franziska et al. · Frontiers in medicine · 2022 · DOI
Quick Summary
This study looked at antibody responses to Epstein-Barr virus (EBV), a common virus linked to ME/CFS onset in some patients. Researchers analyzed blood samples from 92 ME/CFS patients and 50 healthy people, testing reactions to over 3,000 EBV proteins. They found that in patients whose ME/CFS started after a suspected EBV infection, two specific viral proteins triggered stronger antibody responses than in healthy controls. These antibody patterns could correctly identify about 83% of infected patients and 72% of healthy people, suggesting they might become useful diagnostic markers.
Why It Matters
ME/CFS lacks reliable diagnostic biomarkers, making diagnosis difficult and delaying patient care. If validated in future studies, these EBV antibody patterns could provide an objective test to confirm ME/CFS in patients whose illness began with an infection, helping distinguish ME/CFS from other conditions. This work also advances understanding of which EBV antigens are involved in ME/CFS pathogenesis.
Observed Findings
Patients with ME/CFS preceded by putative infection showed significantly stronger IgG responses to two EBV antigens (EBNA4_0529 and EBNA6_0070) compared to healthy controls.
When analyzing the entire ME/CFS cohort without stratification by disease trigger, no antibody responses could distinguish patients from healthy controls.
A classification model using the two candidate antigens plus age and gender achieved 83.3% sensitivity and 72.0% specificity for case-control discrimination.
Patients with non-infectious or unknown disease triggers did not show distinguishing antibody patterns compared to controls.
Inferred Conclusions
Certain EBV-derived antigens may serve as biomarkers for ME/CFS diagnosis specifically in patients with documented infectious disease onset.
The diagnostic value of these antibody responses is restricted to a disease subgroup, suggesting EBV involvement varies across ME/CFS patients.
Age and gender interactions with antibody responses are relevant factors for diagnostic classification models.
Independent validation in a separate cohort is necessary before clinical application of these candidate biomarkers.
Remaining Questions
Will these two EBV antigens show similar diagnostic accuracy when tested in an independent cohort of ME/CFS patients?
What This Study Does Not Prove
This study does not prove that EBV causes ME/CFS or that these antibody responses are the mechanism of disease. The findings are specific to patients whose ME/CFS began with a suspected infection—they do not apply to all ME/CFS patients. The results require independent validation in a new patient population before clinical use, as this was a secondary analysis of previously published data.